Navigation Links
Innocoll Provides an Update on its Range of Advanced Wound Care and Related Collagen-based Products
Date:9/19/2011

ASHBURN, Va., Sept. 19, 2011 /PRNewswire/ -- Innocoll, Inc. announced the following update for its range of advanced wound care and related collagen-based products. Based on a series of recent regulatory approvals and product listings, Innocoll has added six more products in a variety of sponge, film, bilayer, powder, gel and spray formats that are available for commercialization in the US, EU and other markets such as Canada and New Zealand. These products include:  

  • CollaCare®, a range of advanced bioactive wound dressings for the management of chronic and acute wounds available in sponge, film and powder formats.
  • CollaCare® Dental, a lyophilized collagen matrix for the management of oral wounds including periodontal and other dental surgical wounds.  
  • Collexa®, an advanced bilayer wound dressing for the management of heavily exudating chronic wounds and burns.
  • Lidocoll®, an OTC topical analgesic available in collagen-based spray and gel formats containing 4% lidocaine hydrochloride for the relief of pain associated with minor burns, cuts, and skin irritations.
  • CollaGentle™, a collagen-based spray for skin conditioning and moisturizing.
  • Zorpreva™, a series of collagen-based absorbable hemostats for use in surgery including maxillofacial and dental surgeries.

Commenting on the update, Dr. Michael Myers, Innocoll's President and CEO said, "We have successfully expanded our portfolio of collagen-based products to include a wide range of presentations and applications. We are actively preparing for the commercialization of these products in the near future."

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical dev
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
2. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
3. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
4. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
5. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
10. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
11. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... positive,results from a Phase I trial of R1507, a ... in patients with solid,tumors. IGF-1 is one of the ... pathways, which promote cell growth and cell survival. The,IGF-1R ... role in mediating,the resistance to cytotoxic drugs and EGFR/HER2-targeted ...
... tolerated dose for trodusquemine determined, PLYMOUTH MEETING, ... ) today presented data from its dose-escalating,Phase 1 ... candidate for the treatment of obesity. In the ... clinical doses, and,no serious adverse events were seen ...
Cached Medicine Technology:Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507) 2Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507) 3Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507) 4Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 5
(Date:4/23/2014)... could help doctors predict which patients might suffer potentially ... The program, which assesses brain scans using pattern recognition ... passport control, has been developed by researchers at Imperial ... the Wellcome Trust, which used the software are published ... Stroke affects over 15 million people each year worldwide. ...
(Date:4/23/2014)... the United States, it may come as a surprise that ... food due to lack of money or other financial resources. ... University of Illinois using data from the National Health and ... dealing with hunger are also facing negative health and nutrition ... age 60 faced the threat of hungerthat translates to 4.8 ...
(Date:4/23/2014)... the journal Oncotarget , explored tumour heterogeneity ... their own DNA signatures within the same cancer. ... effective, targeted treatment strategies. , Firstly they confirmed ... either the KRAS or BRAF mutation. Secondly, they ... gene mutation have that specific mutation present uniformly ...
(Date:4/22/2014)... and industry leaders visited the New Jersey Institute ... Joel S. Bloom for the launch of the ... that provides a new model for business innovation ... education assets and investment. U.S. Senator Cory Booker, ... Joe Taylor, New Jersey Lieutenant Governor Kim Guadagno, ...
(Date:4/22/2014)... cancers are small cell lung cancers (SCLC), which ... However, researchers at Virginia Commonwealth University Massey Cancer ... leading to this resistance that may lead to ... mediating B-cell lymphoma 2 (Bcl-2) family proteins, which ... their function, this family of proteins can trigger ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... MINNEAPOLIS, July 27 ATS Medical, Inc. (Nasdaq: ATSI ... today announced that it will release financial results for the second ... August 3, 2009. The Company will host a conference call ... Time (2:00 p.m. Pacific Time) to discuss its second quarter results ...
... ... ... 2009 -- Silver Creek Systems®, the pioneer and leader in automated Data Mastering, announced ... Management from Forrester Research, Inc., author Rob Karel recognizes the value the company delivers ...
... Midbrook is using ... use in hospitals and other medical facilities that are working to prevent infections. , ... (Vocus) July 27, 2009 -- Midbrook, ... case carts and storage cabinets has begun to use copper alloys as an alternative ...
... ... a large pill. Impact Nutritionals, Inc. launches its first product, S7 Prenatal™ Drink Mix, the ... premise that supplements should taste good and be good for you. To celebrate the launch, ... , ...
... ... in a state of crisis largely due to the failure of highly ... individuals. In his latest article, The Perfect Health Plan: Proven, Safe, Effective, ... occur per year from these FDA approved, properly prescribed, and properly administered ...
... Government health officials from 13 African countries today ... medical laboratories, starting a process that the World Health ... an historic step to strengthen health systems and lead ... of Africa,s laboratories are now accredited, in part because ...
Cached Medicine News:Health News:ATS Medical Announces Second Quarter 2009 Earnings Release Date and Conference Call 2Health News:Leading Independent Analyst Firm States Silver Creek Systems Holds A Virtual Monopoly In Delivering Advanced Product Data Quality Capabilities 2Health News:Midbrook Utilizes Copper in Medical Environments 2Health News:Moms, Registered Dietitian, Develop the First All-In-One Prenatal Vitamin in a Great Tasting Drink Mix 2Health News:Research Scientist Reports On Time-Tested Solution To Current Medical Crisis 2Health News:Research Scientist Reports On Time-Tested Solution To Current Medical Crisis 3Health News:Research Scientist Reports On Time-Tested Solution To Current Medical Crisis 4Health News:Leading health organizations launch new accreditation process for laboratories across Africa 2Health News:Leading health organizations launch new accreditation process for laboratories across Africa 3Health News:Leading health organizations launch new accreditation process for laboratories across Africa 4
... IV and the Penilab V have an exceptionally sensitive ... is similar to the Model 1061 shown below, but ... added later. The Penilab V has a Doppler. ... accessories you'll need to get started. Latex rubber ...
... is designed for vascular labs already ... Its primary use will be ... a cuff with air. Blood ... cuffs - a proximal occluding cuff ...
... With its outstanding optical performance, the ... light used for all types of applications. ... micro-lens technology complies with the highest standards ... provides excellent shadow control within the surgical ...
... The DRE-200 ESU units use dedicated digital ... for processing data. This hardware allows parallel ... processing throughput, measuring tissue impedance 5000 times ... processed digitally, being converted to analog only ...
Medicine Products: